Prolonged prostate-specific antigen response in flutamide withdrawal syndrome despite disease progression

Lynn Longmore, John P. Foley, Thomas A Rozanski, Betsy Higgins, Ian M. Thompson

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Flutamide withdrawal syndrome is characterized by a decrease in prostate-specific antigen (PSA) after flutamide withdrawal in a subset of patients with progressing metastatic carcinoma of the prostate. It is generally hypothesized to be due to a point mutation in the androgen receptor that allows the antiandrogen to function as an agonist, leading to a dramatic and rapid PSA response. We describe a patient with androgen-independent prostate cancer in whom PSA continued to decrease for a period of 15 months after flutamide withdrawal. With continuing fall in PSA, the patient had unequivocal progression of disease seen on bone scan. This case illustrates the potential decoupling of PSA response from disease status in flutamide withdrawal. It also illustrates the need for continued clinical evaluation of patients with metastatic prostate cancer, even in the face of PSA response.

Original languageEnglish (US)
Pages (from-to)573-575
Number of pages3
JournalSouthern Medical Journal
Volume91
Issue number6
StatePublished - Jun 1998

Fingerprint

Flutamide
Prostate-Specific Antigen
Disease Progression
Prostatic Neoplasms
Androgen Antagonists
Androgen Receptors
Point Mutation
Androgens
Prostate
Carcinoma
Bone and Bones

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Longmore, L., Foley, J. P., Rozanski, T. A., Higgins, B., & Thompson, I. M. (1998). Prolonged prostate-specific antigen response in flutamide withdrawal syndrome despite disease progression. Southern Medical Journal, 91(6), 573-575.

Prolonged prostate-specific antigen response in flutamide withdrawal syndrome despite disease progression. / Longmore, Lynn; Foley, John P.; Rozanski, Thomas A; Higgins, Betsy; Thompson, Ian M.

In: Southern Medical Journal, Vol. 91, No. 6, 06.1998, p. 573-575.

Research output: Contribution to journalArticle

Longmore, L, Foley, JP, Rozanski, TA, Higgins, B & Thompson, IM 1998, 'Prolonged prostate-specific antigen response in flutamide withdrawal syndrome despite disease progression', Southern Medical Journal, vol. 91, no. 6, pp. 573-575.
Longmore L, Foley JP, Rozanski TA, Higgins B, Thompson IM. Prolonged prostate-specific antigen response in flutamide withdrawal syndrome despite disease progression. Southern Medical Journal. 1998 Jun;91(6):573-575.
Longmore, Lynn ; Foley, John P. ; Rozanski, Thomas A ; Higgins, Betsy ; Thompson, Ian M. / Prolonged prostate-specific antigen response in flutamide withdrawal syndrome despite disease progression. In: Southern Medical Journal. 1998 ; Vol. 91, No. 6. pp. 573-575.
@article{e1f4c72e0165442f913c4c537c04100a,
title = "Prolonged prostate-specific antigen response in flutamide withdrawal syndrome despite disease progression",
abstract = "Flutamide withdrawal syndrome is characterized by a decrease in prostate-specific antigen (PSA) after flutamide withdrawal in a subset of patients with progressing metastatic carcinoma of the prostate. It is generally hypothesized to be due to a point mutation in the androgen receptor that allows the antiandrogen to function as an agonist, leading to a dramatic and rapid PSA response. We describe a patient with androgen-independent prostate cancer in whom PSA continued to decrease for a period of 15 months after flutamide withdrawal. With continuing fall in PSA, the patient had unequivocal progression of disease seen on bone scan. This case illustrates the potential decoupling of PSA response from disease status in flutamide withdrawal. It also illustrates the need for continued clinical evaluation of patients with metastatic prostate cancer, even in the face of PSA response.",
author = "Lynn Longmore and Foley, {John P.} and Rozanski, {Thomas A} and Betsy Higgins and Thompson, {Ian M.}",
year = "1998",
month = "6",
language = "English (US)",
volume = "91",
pages = "573--575",
journal = "Southern Medical Journal",
issn = "0038-4348",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Prolonged prostate-specific antigen response in flutamide withdrawal syndrome despite disease progression

AU - Longmore, Lynn

AU - Foley, John P.

AU - Rozanski, Thomas A

AU - Higgins, Betsy

AU - Thompson, Ian M.

PY - 1998/6

Y1 - 1998/6

N2 - Flutamide withdrawal syndrome is characterized by a decrease in prostate-specific antigen (PSA) after flutamide withdrawal in a subset of patients with progressing metastatic carcinoma of the prostate. It is generally hypothesized to be due to a point mutation in the androgen receptor that allows the antiandrogen to function as an agonist, leading to a dramatic and rapid PSA response. We describe a patient with androgen-independent prostate cancer in whom PSA continued to decrease for a period of 15 months after flutamide withdrawal. With continuing fall in PSA, the patient had unequivocal progression of disease seen on bone scan. This case illustrates the potential decoupling of PSA response from disease status in flutamide withdrawal. It also illustrates the need for continued clinical evaluation of patients with metastatic prostate cancer, even in the face of PSA response.

AB - Flutamide withdrawal syndrome is characterized by a decrease in prostate-specific antigen (PSA) after flutamide withdrawal in a subset of patients with progressing metastatic carcinoma of the prostate. It is generally hypothesized to be due to a point mutation in the androgen receptor that allows the antiandrogen to function as an agonist, leading to a dramatic and rapid PSA response. We describe a patient with androgen-independent prostate cancer in whom PSA continued to decrease for a period of 15 months after flutamide withdrawal. With continuing fall in PSA, the patient had unequivocal progression of disease seen on bone scan. This case illustrates the potential decoupling of PSA response from disease status in flutamide withdrawal. It also illustrates the need for continued clinical evaluation of patients with metastatic prostate cancer, even in the face of PSA response.

UR - http://www.scopus.com/inward/record.url?scp=0031749745&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031749745&partnerID=8YFLogxK

M3 - Article

C2 - 9634122

AN - SCOPUS:0031749745

VL - 91

SP - 573

EP - 575

JO - Southern Medical Journal

JF - Southern Medical Journal

SN - 0038-4348

IS - 6

ER -